Stefanos Theoharis
Chief Executive Officer OneChain Immunotherapeutics
Stefanos Theoharis brings over 20 years of broad experience in the cell and gene therapy space, business development, program management, manufacturing and basic research brings a deep knowledge CGT sector. Former CBO of Bone Therapeutics, Belgium-based company, developing specialized cell therapies for orthopaedic disorders. Prior to that he was Senior Vice-President at Cell Medica, and CBO at apceth GmbH. He also held positions, among others, as Director Business Development at Roche, focused on partnering activities in emerging science and technologies and M&A Analyst at Lazard, the global investment bank. He holds a PhD in gene therapy and immunology from Imperial College London.
Seminars
Thursday 30th July 2026
A Novel Differentiated In Vivo Lentiviral Platform
9:00 am
- Analysis of the limitations in existing lentiviral systems identified engineering constraints that shaped the starting architecture for a new lentiviral platform, enabling clearer mechanistic differentiation
- Preclinical proof of concept readouts and benchmarking data will be presented for the first time
